The Cost-Effectiveness Conundrum of Protecting Infants from RSV
A new cost-effectiveness analysis published in *Pediatrics* evaluates immunization strategies against respiratory syncytial virus (RSV) in low-risk infants. The study models the Advisory Committee on Immunization Practices (ACIP)-recommended approach, which combines maternal RSVpreF vaccination with infant nirsevimab (a monoclonal antibody), against a strategy using nirsevimab alone. From a strict healthcare sector perspective focused on direct medical costs, neither strategy met the standard cost-effectiveness threshold compared to no intervention. However, when adopting a broader societal perspective that includes factors like caregiver productivity loss, the combined maternal and infant immunization strategy became cost-effective. The nirsevimab-only strategy was not cost-effective compared to the combined approach due to higher product costs, though it would be a viable alternative if maternal vaccination were unavailable.
Study Significance: This analysis provides critical data for public health officials and clinicians debating resource allocation for infant immunology. For professionals in vaccine development and immunology, it underscores the economic impact of leveraging both humoral immunity (via maternal vaccination) and passive antibody therapy. The findings advocate for integrated obstetric and pediatric care to implement the most societally beneficial strategy for preventing severe RSV disease.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
